247 related articles for article (PubMed ID: 30547193)
21. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study.
Xiao Y; Cheng H; Wang L; Yu X
J Gynecol Oncol; 2020 Jan; 31(1):e2. PubMed ID: 31788992
[TBL] [Abstract][Full Text] [Related]
22. Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study.
Li H; Zeng J; Jin X; Yu X; Zhou G; Hong W
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1083-1090. PubMed ID: 30937519
[TBL] [Abstract][Full Text] [Related]
23. Short-term efficacy and safety of apatinib in advanced squamous cell carcinoma of the lung.
Li X; Le L; Han L; Zhang Y; Sun S
Indian J Cancer; 2017; 54(3):547-549. PubMed ID: 29798956
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
[TBL] [Abstract][Full Text] [Related]
25. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
26. The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.
Ding L; Li QJ; You KY; Jiang ZM; Yao HR
Medicine (Baltimore); 2016 May; 95(20):e3598. PubMed ID: 27196461
[TBL] [Abstract][Full Text] [Related]
27. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
[TBL] [Abstract][Full Text] [Related]
28. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study.
Yang H; Chen M; Mei Z; Xie C; Zhou Y; Qiu H
Cancer Med; 2021 Jul; 10(13):4282-4290. PubMed ID: 33987959
[TBL] [Abstract][Full Text] [Related]
30. The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.
Liu M; Wang X; Li H; Xu L; Jing L; Jiang P; Liu B; Li Y
Thorac Cancer; 2019 Oct; 10(10):1868-1878. PubMed ID: 31486270
[TBL] [Abstract][Full Text] [Related]
31. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
Yan X; Wang Q; Wang H; Li P; Zhang G; Zhang M; Zheng X; Yang J; Zhang X; Ma Z
J Cancer Res Clin Oncol; 2019 Jan; 145(1):235-240. PubMed ID: 30293117
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study.
Geng Q; Shen H; Zhu W; Lu Y; Wang M; Jiang H; Li D
Onco Targets Ther; 2020; 13():11529-11535. PubMed ID: 33204107
[TBL] [Abstract][Full Text] [Related]
33. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract][Full Text] [Related]
34. Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review.
Liu YY; Chen T; Shen D; Zhang WY; Wang CG; Jiang JH; Zeng DX
J Int Med Res; 2020 Mar; 48(3):300060519887276. PubMed ID: 31847652
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma.
Liu G; Wang Y; Wang C; He Y; E M
Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1423-1430. PubMed ID: 33115264
[No Abstract] [Full Text] [Related]
36. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
Guo Y; Tang J; Huang XE; Cao J
Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
[TBL] [Abstract][Full Text] [Related]
37. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
Li L; Kong F; Zhang L; Li X; Fu X; Wang X; Wu J; Zhang F; Ren L; Zhang M
Invest New Drugs; 2020 Dec; 38(6):1847-1853. PubMed ID: 32363427
[TBL] [Abstract][Full Text] [Related]
38. Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma.
Zeng DX; Wang CG; Lei W; Huang JA; Jiang JH
Oncotarget; 2017 Sep; 8(39):66248-66253. PubMed ID: 29029508
[TBL] [Abstract][Full Text] [Related]
39. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
[TBL] [Abstract][Full Text] [Related]
40. Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.
Xu Y; Huang Z; Lu H; Yu X; Li Y; Li W; Chen J; Chen M; Gong L; Chen K; Qin J; Xu X; Jin Y; Zhao J; Shi X; Han N; Xie F; Zhang P; Xu W; Fan Y
Br J Cancer; 2019 Oct; 121(8):640-646. PubMed ID: 31523058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]